Zobrazeno 1 - 10
of 733
pro vyhledávání: '"Natasha, Rekhtman"'
Autor:
Alissa J. Cooper, MD, Natasha Rekhtman, MD, PhD, Marina K. Baine, MD, PhD, Marie C. Thomas, DNP, FNP-C, Alia C. Lynch, PharmD, BCOP, Ryan D. Gentzler, MD, MS
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100750- (2024)
Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-exp
Externí odkaz:
https://doaj.org/article/a8288d90bce449ed811d1abf0dde896c
Autor:
Rebecca Caeser, Jacklynn V. Egger, Shweta Chavan, Nicholas D. Socci, Caitlin Byrne Jones, Faruk Erdem Kombak, Marina Asher, Michael H. Roehrl, Nisargbhai S. Shah, Viola Allaj, Parvathy Manoj, Sam E. Tischfield, Amanda Kulick, Maximiliano Meneses, Christine A. Iacobuzio-Donahue, W. Victoria Lai, Umeshkumar Bhanot, Marina K. Baine, Natasha Rekhtman, Travis J. Hollmann, Elisa de Stanchina, John T. Poirier, Charles M. Rudin, Triparna Sen
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Creating accurate models of small cell lung cancer is essential to ensure the clinical relevance of results. Here, the authors create patient derived xenograft models from 33 patients and show, through multi-omics sequencing, that these models retain
Externí odkaz:
https://doaj.org/article/6db844e570e04ea595ba52c8f6bba923
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRET
Externí odkaz:
https://doaj.org/article/c9aadc1f6bbc44acba731c2a7dcb7aef
Autor:
Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian A. Zhan, Maysun M. Hasan, Shweta S. Chavan, Fanli Meng, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah, Joseph M. Chan, Metamia Ciampricotti, Andrew Chow, Michael Offin, Jordana Ray-Kirton, Jacklynn D. Egger, Umesh K. Bhanot, Irina Linkov, Marina Asher, Michael H. Roehrl, Katia Ventura, Juan Qiu, Elisa de Stanchina, Jason C. Chang, Natasha Rekhtman, Brian Houck-Loomis, Richard P. Koche, Helena A. Yu, Triparna Sen, Charles M. Rudin
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-19 (2021)
Abstract Background Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell and squamous cell (LUSC
Externí odkaz:
https://doaj.org/article/4c6ed1ab46b04936a848bae9af7bc67d
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
Autor:
Athea Vichas, Amanda K. Riley, Naomi T. Nkinsi, Shriya Kamlapurkar, Phoebe C. R. Parrish, April Lo, Fujiko Duke, Jennifer Chen, Iris Fung, Jacqueline Watson, Matthew Rees, Austin M. Gabel, James D. Thomas, Robert K. Bradley, John K. Lee, Emily M. Hatch, Marina K. Baine, Natasha Rekhtman, Marc Ladanyi, Federica Piccioni, Alice H. Berger
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-19 (2021)
RIT1 mutations are mutually exclusive with other lung cancer drivers and lack targeted therapies. Here the authors examine genetic dependencies of mutant RIT1 with genome-wide CRISPR screens, revealing synergy between RIT1 and YAP1, and increased sen
Externí odkaz:
https://doaj.org/article/06e749d7f425413a87006cc1366f2c04
Autor:
Noura J. Choudhury, MD, Jaime L. Schneider, MD, PhD, Tejas Patil, MD, Viola W. Zhu, MD, PhD, Debra A. Goldman, MS, Soo-Ryum Yang, MD, Christina J. Falcon, MPH, Andrew Do, BS, Yunan Nie, MD, Andrew J. Plodkowski, MD, Jamie E. Chaft, MD, Subba R. Digumarthy, MD, Natasha Rekhtman, MD, PhD, Maria E. Arcila, MD, Alexia Iasonos, PhD, Sai-Hong I. Ou, MD, PhD, Jessica J. Lin, MD, Alexander Drilon, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100187- (2021)
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype ha
Externí odkaz:
https://doaj.org/article/81bc0a6f5dc849f182e47505ceaaaec1
Autor:
Noura J. Choudhury, Antonio Marra, Jane S.Y. Sui, Jessica Flynn, Soo-Ryum Yang, Christina J. Falcon, Pier Selenica, Adam J. Schoenfeld, Natasha Rekhtman, Daniel Gomez, Michael F. Berger, Marc Ladanyi, Maria Arcila, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Glenn Heller, Jorge S. Reis-Filho, Helena A. Yu
Publikováno v:
Journal of Thoracic Oncology. 18:463-475
Preferred first-line treatment for patients with metastatic EGFR-mutant lung cancer is osimertinib, yet it is not known if patient outcomes may be improved by identifying and intervening upon molecular markers associated with therapeutic resistance.A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c319c80baa5ae91d6606cbab73e1f761
https://doi.org/10.1016/j.jtho.2022.11.022
https://doi.org/10.1016/j.jtho.2022.11.022
Autor:
Corrin A. Wohlhieter, Allison L. Richards, Fathema Uddin, Christopher H. Hulton, Àlvaro Quintanal-Villalonga, Axel Martin, Elisa de Stanchina, Umeshkumar Bhanot, Marina Asher, Nisargbhai S. Shah, Omar Hayatt, Darren J. Buonocore, Natasha Rekhtman, Ronglai Shen, Kathryn C. Arbour, Mark Donoghue, John T. Poirier, Triparna Sen, Charles M. Rudin
Publikováno v:
Cell Reports, Vol 33, Iss 9, Pp 108444- (2020)
Summary: Concurrent loss-of-function mutations in STK11 and KEAP1 in lung adenocarcinoma (LUAD) are associated with aggressive tumor growth, resistance to available therapies, and early death. We investigated the effects of coordinate STK11 and KEAP1
Externí odkaz:
https://doaj.org/article/79f1bb5015774d05860c9599ee982825
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srushti Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/5da51ab03db947f7a3ffd0a6118bb43a
Autor:
Maria E. Arcila, MD, Soo-Ryum Yang, MD, Amir Momeni, MD, Douglas A. Mata, MD, Paulo Salazar, BS, Roger Chan, BS, Daniela Elezovic, BS, Ryma Benayed, PhD, Ahmet Zehir, PhD, Darren J. Buonocore, MD, Natasha Rekhtman, MD, Oscar Lin, MD, Marc Ladanyi, MD, Khedoudja Nafa, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100077- (2020)
Introduction: For patients with advanced NSCLC, cytologic samples may be the only diagnostic specimen available for molecular profiling. Although both rapid and comprehensive assessment are essential in this setting, an integrated multitest approach
Externí odkaz:
https://doaj.org/article/bb5a2173dfd147caaec46e5ca0cb4e9f